BIOPHYTIS confirms that Sarconeos modulates the Renin-Angiotensin System and activates muscular metabolism in the SARA-PK clinical trial
May 03, 2017 14:00 ET
|
BIOPHYTIS SA
PARIS, May 03, 2017 (GLOBE NEWSWIRE) -- BIOPHYTIS (Alternext Paris:ALBPS), a biotechnology company specializing in the development of drug candidates to treat age-related diseases, announced it...
BIOPHYTIS: 2016 Full Year Results
April 27, 2017 12:07 ET
|
BIOPHYTIS SA
Extension to the USA of the Sarcopenia clinical programConfirmation of the good safety profile of Sarconeos in SARA-PK clinical trialAuthorizations to launch SARA-OBS clinical study, in which...
BIOPHYTIS secures funding for phase 2B clinical trial in Sarcopenia, SARA-INT
April 04, 2017 07:00 ET
|
BIOPHYTIS SA
Completes €3.7 million private placementArranges a bond financing of €15 million PARIS, April 04, 2017 (GLOBE NEWSWIRE) -- BIOPHYTIS (Alternext Paris:ALBPS), a biotechnology company specializing in...
BIOPHYTIS opens the first clinical centers in Europe and starts the recruitment of sarcopenic patients for SARA-OBS study
March 27, 2017 08:00 ET
|
BIOPHYTIS SA
PARIS, March 27, 2017 (GLOBE NEWSWIRE) -- BIOPHYTIS (Alternext Paris:ALBPS), a biotechnology company specialized in the development of drug candidates to treat ageing diseases, announced that the...
BIOPHYTIS to present four scientific studies at the International Conference on Frailty & Sarcopenia Research (ICFSR) in Barcelona
March 22, 2017 08:00 ET
|
BIOPHYTIS SA
PARIS, March 22, 2017 (GLOBE NEWSWIRE) -- BIOPHYTIS (Alternext Paris:ALBPS), a biotechnology company specializing in the development of drug candidates to treat diseases of aging, announced it will...
BIOPHYTIS: Full results of SARA-PK study confirm Sarconeos’ good pharmacokinetic profile in elderly patients
March 02, 2017 08:00 ET
|
BIOPHYTIS SA
PARIS, March 02, 2017 (GLOBE NEWSWIRE) -- BIOPHYTIS (Alternext Paris:ALBPS), a biotechnology company specializing in the development of drug candidates to treat diseases of ageing, announces today...
BIOPHYTIS Announces Successful Completion of SARA-PK Clinical Study for Sarconeos in Sarcopenia Confirming Safety Profile
November 30, 2016 08:00 ET
|
BIOPHYTIS SA
ROMAINVILLE, France, Nov. 30, 2016 (GLOBE NEWSWIRE) -- BIOPHYTIS (Alternext Paris:ALBPS), a biotechnology company specialized in the development of drug candidates to treat aging diseases, announces...
BIOPHYTIS received regulatory authorizations to conduct SARA-OBS study in sarcopenia patients
November 22, 2016 07:30 ET
|
BIOPHYTIS SA
ROMAINVILLE, France, Nov. 22, 2016 (GLOBE NEWSWIRE) -- BIOPHYTIS (Alternext Paris:ALBPS) a biotechnology company specialized in the development of drug candidates to treat aging diseases, announces...
BIOPHYTIS Presenting Four Posters on Sarconeos at 9th International Conference on Cachexia, Sarcopenia, and Muscle Wasting
November 15, 2016 07:30 ET
|
BIOPHYTIS SA
ROMAINVILLE, France, Nov. 15, 2016 (GLOBE NEWSWIRE) -- BIOPHYTIS (Alternext Paris:ALBPS), a biotechnology company specializing in the development of drug candidates to treat diseases of aging,...
BIOPHYTIS chooses Patheon to produce the clinical batches of Macuneos, its AMD drug candidate that will enter Phase 2B
October 24, 2016 07:30 ET
|
BIOPHYTIS SA
ROMAINVILLE, France, Oct. 24, 2016 (GLOBE NEWSWIRE) -- BIOPHYTIS (Alternext Paris:ALBPS), a biotechnology company specializing in the development of drug candidates to treat diseases of aging,...